Search

Your search keyword '"Nogué, Miquel"' showing total 14 results
Start Over Author "Nogué, Miquel"
14 results on '"Nogué, Miquel"'

1. Determinants of activity and efficacy of anti-PD1/PD-L1 therapy in patients with advanced solid tumors recruited in a clinical trials unit: a longitudinal prospective biomarker-based study

Author

García-Corbacho, Javier, Indacochea, Alberto, González Navarro, Azucena E., Victoria, Iván, Moreno, Débora, Pesántez, David, Angelats, Laura, Modrego-Sanchez, Andrea, Sanfeliu, Esther, Castillo, Oleguer, Blasco, Paula, Mezquita, Laura, Viñolas, Nuria, Nogué, Miquel, Galván, Patricia, Adamo, Barbara, Basté, Neus, Sauri, Tamara, Juan, Manel, Prat, Aleix, and Schettini, Francesco

Published
2023
Full Text
View/download PDF

2. Correction to: Determinants of activity and efficacy of anti-PD1/PD-L1 therapy in patients with advanced solid tumors recruited in a clinical trials unit: a longitudinal prospective biomarker-based study

Author

García-Corbacho, Javier, Indacochea, Alberto, González Navarro, Azucena E., Victoria, Iván, Moreno, Débora, Pesántez, David, Angelats, Laura, Modrego-Sanchez, Andrea, Sanfeliu, Esther, Castillo, Oleguer, Blasco, Paula, Mezquita, Laura, Viñolas, Nuria, Nogué, Miquel, Galván, Patricia, Adamo, Barbara, Basté, Neus, Sauri, Tamara, Juan, Manel, Prat, Aleix, and Schettini, Francesco

Published
2023
Full Text
View/download PDF

3. Total neoadjuvant therapy with or without aflibercept in rectal cancer: Three-year results of GEMCAD-1402

Author

Pesántez, David, primary, ten Hoorn, Sanne, additional, Machado, Isidro, additional, García-Albéniz, Xabier, additional, Rodríguez-Salas, Nuria, additional, Heredia-Soto, Victoria, additional, Viñal, David, additional, Pericay, Carles, additional, García-Carbonero, Rocio, additional, Losa, Ferran, additional, Alonso, Vicente, additional, Vera, Ruth, additional, Feliu Batlle, Jaime, additional, Gallego, Javier, additional, Salud, Antonieta, additional, Nogué, Miquel, additional, Layos, Laura, additional, Montagut, Clara, additional, Capdevila, Jaume, additional, Vermeulen, Louis, additional, Maurel, Joan, additional, and Fernandez-Martos, Carlos, additional

Published
2023
Full Text
View/download PDF

4. Total neoadjuvant therapy with or without aflibercept in rectal cancer: 3-year results of GEMCAD-1402.

Author

Pesántez, David, Hoorn, Sanne ten, Machado, Isidro, García-Albéniz, Xabier, Rodríguez-Salas, Nuria, Heredia-Soto, Victoria, Viñal, David, Pericay, Carles, García-Carbonero, Rocio, Losa, Ferran, Alonso, Vicente, Vera, Ruth, Batlle, Jaime Feliu, Gallego, Javier, Salud, Antonieta, Nogué, Miquel, Layos, Laura, Montagut, Clara, Capdevila, Jaume, and Vermeulen, Louis

Subjects
RECTAL cancer, NEOADJUVANT chemotherapy, AFLIBERCEPT, MAGNETIC resonance, PROGRESSION-free survival, CHEMORADIOTHERAPY
Abstract

Background The results of the Grupo Español Multidisciplinar en Cáncer Digestivo (GEMCAD)-1402 phase II randomized trial suggested that adding aflibercept to modified fluorouracil, oxaliplatin, and leucovorin (mFOLFOX6) induction, followed by chemoradiation and surgery, could increase the pathological complete response (pCR) rate in patients with high-risk, locally advanced rectal cancer. Here we update results up to 3 years of follow-up and evaluate the predictive value of consensus molecular subtypes identified with immunohistochemistry (IHC). Methods Patients with magnetic resonance imaging–defined T3c-d and/or T4 and/or N2 rectal adenocarcinoma in the middle or distal third were randomly assigned to mFOLFOX6 induction, with aflibercept (mF+A; n   =   115) or without aflibercept (mF; n   =   65), followed by capecitabine plus radiotherapy and surgery. The risk local relapse, distant metastases, disease-free survival (DFS), and overall survival (OS) were estimated at 3 years. Selected samples were classified via IHC into immune-infiltrate, epithelial, or mesenchymal subtypes. Results mF+A and mF had 3-year DFS of 75.2% (95% confidence interval [CI] = 66.1% to 82.2%) and 81.5% (95% CI = 69.8% to 89.1%), respectively; 3-year OS of 89.3% (95% CI = 82.0% to 93.8%) and 90.7% (95% CI = 80.6% to 95.7%), respectively; 3-year cumulative local relapse incidences of 5.2% (95% CI = 1.9% to 11.0%) and 6.1% (95% CI = 1.7% to 15.0%), respectively; and 3-year cumulative distant metastases rates of 17.3% (95% CI = 10.9% to 25.5%) and 16.9% (95% CI = 8.7% to 28.2%), respectively. pCRs were achieved in 27.5% (n   =   22 of 80) and 0% (n   =   0 of 10) of patients with epithelial and mesenchymal subtypes, respectively. Conclusion Adding aflibercept to mFOLFOX6 induction was not associated with improved DFS or OS. Our findings suggested that consensus molecular subtypes identified with IHC subtypes could be predictive of pCR with this treatment. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

7. Randomised study of tegafur and oral leucovorin versus intravenous 5-fluorouracil and leucovorin in patients with advanced colorectal cancer

Author

Nogué, Miquel, Salud, Antonieta, Batiste-Alentorn, Eduard, Saigí, Eugeni, Losa, Ferran, Cirera, Lluís, Méndez, Miguel, Campos, Juan Manuel, Galan, Antonio, Escudero, Pilar, Arcusa, Angels, Manzano, Hermini, de Mendizábal, Edelmira Vélez, de Olaguer, Joaquim Pérez, Boleda, Montserrat, Guasch, Immaculada, and Vicente, Pilar

Published
2005
Full Text
View/download PDF

10. Effect of Aflibercept Plus Modified FOLFOX6 Induction Chemotherapy Before Standard Chemoradiotherapy and Surgery in Patients With High-Risk Rectal Adenocarcinoma

Author

Fernández-Martos, Carlos, primary, Pericay, Carles, additional, Losa, Ferran, additional, García-Carbonero, Rocio, additional, Layos, Laura, additional, Rodríguez-Salas, Nuria, additional, Martin-Richard, Marta, additional, Alonso-Orduña, Vicente, additional, Vera, Ruth, additional, Gallego, Javier, additional, Capdevila, Jaume, additional, Salud, Antonieta, additional, Nogué, Miquel, additional, Maurel, Joan, additional, Guash, Inmaculada, additional, Montagut, Clara, additional, Lopez, Carlos, additional, Macias, Ismael, additional, Jain, Rakesh K., additional, and Garcia-Albeniz, Xabier, additional

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results